Abstract
Background: We aimed to explore whether the expression of serum miR-222-3p might contribute to early prediction of therapeutic response, clinical outcomes, and adverse events for HER2-positive breast cancer patients receiving neoadjuvant therapy (NAT).Methods: A total of 65 HER2-positive breast cancer patients receiving NAT were analyzed. The concentration of serum miR-222-3p was detected by quantitative real-time PCR. Logistic regression analysis was used to identify the association of serum miR-222-3p with pathological complete response (pCR). The relationship of serum miR-222-3p with disease-free survival (DFS) and overall survival (OS) was examined via log-rank test and Cox proportional hazards analysis. The ordered logistic regression was applied to evaluate the association between serum miR-222-3p and adverse events.Results: The miR-222-3p low group was more likely to achieve pCR [odds ratio (OR) = 0.258, P = 0.043]. The interaction between miR-222-3p and presenting Ki67 level was also detected for pCR (OR = 49.230, Pinteraction = 0.025). The miR-222-3p low group was correlated with superior DFS (P = 0.029) and OS (P = 0.0037). The expression of serum miR-222-3p was the independent protective factor for trastuzumab-induced cardiotoxicity (P < 0.05) and anemia (P = 0.013).Conclusions: Serum miR-222-3p is the potential factor to predict pCR, survival benefit and trastuzumab-induced cardiotoxicity for HER2-positive breast cancer patients receiving NAT.
Highlights
Neoadjuvant chemotherapy (NAC) is increasingly used in primary breast cancer patients, which aims to improve the operability or breast-conservability, and serves as a good platform for in-vivo tests of various drugs [1,2,3]
The expression of serum miR-222-3p was associated with presenting clinical N stage (P = 0.016) and death (P = 0.046)
The miR-222-3p low group was more likely to achieve pathological complete response (pCR) [OR = 0.258, 95% confidence interval (CI): 0.070-0.958, P = 0.043]
Summary
Neoadjuvant chemotherapy (NAC) is increasingly used in primary breast cancer patients, which aims to improve the operability or breast-conservability, and serves as a good platform for in-vivo tests of various drugs [1,2,3]. Manifold data have demonstrated miR-222-3p Predicting Efficacy and Cardiotoxicity that the addition of trastuzumab to NAC significantly improves the pathological complete response (pCR) rates and thereby results in survival benefit [5,6,7,8]. A majority of HER2positive breast cancer patients still failed to achieve pCR or even progressed despite trastuzumab-based neoadjuvant therapy (NAT) [9,10,11,12]. Given the aggressive biological behavior of HER2positive breast cancer, it hints at a demand to identify potential biomarkers to predict its response to NAT. We aimed to explore whether the expression of serum miR-222-3p might contribute to early prediction of therapeutic response, clinical outcomes, and adverse events for HER2-positive breast cancer patients receiving neoadjuvant therapy (NAT)
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
